Infantile Spasm Treatment Market Rich Product Pipeline and Effective Care Technologies

Overview:

Infantile spasms, or west syndrome, is a rare type of epilepsy in children. It is considered an epileptic encephalopathy or severe brain disorder. It is a complex and rare disorder that can have very serious consequences. It can lead to death in some babies, and cause intellectual disabilities and developmental problems in others. Many children with infantile spasms develop other kinds of epilepsy. It can be cured, but successful treatment often depends on prompt diagnosis.

Infantile spasm is a rare disorder that appears as seizures in infants below 1 year. Infantile spasm causes series of sudden, jerking movements of legs and arms or fast drop of head. The duration of spasm can last up to couple of seconds. Major drugs used for the treatment of infantile spasm include adrenocorticotropic hormone (ACTH), however, due to its side effects, doctors also prefer anti-seizure drugs such as vigabatrin and other steroid therapies.

Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) @ https://www.coherentmarketinsights.com/insight/request-sample/2453

Drivers:

Increasing demand for cost-effective drugs (generic versions) to treat infantile spasm is expected to propel the global infantile spasm treatment market growth over the forecast period. For instance, in May 2018, Amneal Pharmaceuticals announced the launch of vigabatrin for oral solution USP, a generic equivalent for Sabril. Moreover, the company filed Abbreviated New Drug Application (ANDA) to the Food and Drug Administration (FDA) for the tablet form of vigabatrin. Moreover, in July 2018, Aucta Pharmaceuticals begun shipping Vigabatrin 500 mg, following final approval from FDA for its Abbreviated New Drug Application.

Furthermore, market players are adopting various strategies, such as mergers and acquisitions, to strengthen their product portfolio, which in turn is expected to drive growth of the global infantile spasm treatment market. For instance, in 2014, Mallinckrodt plc and Questcor Pharmaceuticals, entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately US$ 5.6 billion.

Segmentation Analysis:

By Product Type:

• • Adrenocorticotropic Hormone (ACTH)
  • Vigabatrin
  • Phase III

By Route of Administration:

• • Oral
  • Parenteral

If opting for the Global version of Infantile Spasm Treatment Market analysis is provided for major regions as follows:

North America (The US, Canada, and Mexico)

Europe (the UK, Germany, France, and Rest of Europe)

Asia Pacific (China, India, and Rest of Asia Pacific)

Latin America (Brazil and Rest of Latin America)

Middle East & Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa)

Major Players:

Major players active in the global infantile spasm treatment market are H. Lundbeck A/S, Catalyst Pharmaceuticals, Mallinckrodt Pharmaceuticals Inc., GW Pharmaceuticals, Retrophin Inc., Insys therapeutics, Valerion Pharma SA, and Anavex Life Sciences Corp.

Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/2453

Table of Content

Global Infantile Spasm Treatment Market Research Report

Section 1: Global Infantile Spasm Treatment Industry Overview

Section 2: Global Economic Impact on Infantile Spasm Treatment Industry

Section 3: Global Market Competition by Industry Producers

Section 4: Global Productions, Revenue (Value), according to Regions

Section 5: Global Supplies (Production), Consumption, Export, Import, geographically

Section 6: Global Productions, Revenue (Value), Price Trend, Product Type

Section 7: Global Market Analysis, on the basis of Application

Section 8: Infantile Spasm Treatment Market Pricing Analysis

Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers

Inquire more about this report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2453

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837